Shire Faces Another Challenge To Patent For Adderall XR

Law360, New York (December 3, 2004, 12:00 AM EST) -- Another generic drug maker has launched a challenge against the patent for Shire Pharmaceuticals Group PLC’s Adderall XR, a blockbuster drug for the treatment of attention deficit and hyperactivity disorders.

Colony Pharmaceuticals Inc. has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of Shire's amphetamine Adderall XR, Shide said.

Adderall is indicated as an integral part of a total treatment program, which typically includes other measures) for patients with the syndrome. The patents protecting Adderall...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.